Gravity Analytica

Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024

DVAX 10.24.2024

SERA-AI Powered Highlights

Drug:HEPLISAV-B HEPLISAV-B®

Drug:CpG-1018 CpG 1018®

Diseases:hepatitis B virus infection

Date of Upcoming Event:2024-11-07

Name of Upcoming Event:Dynavax Q3 2024 Financial Results Conference Call

Full Press Release SEC Filings Our DVAX Tweets

About Gravity Analytica

Recent Filings

EMERYVILLE, Calif.,Oct. 24, 2024/PRNewswire/ --Dynavax Technologies Corporation(Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results onThursday, November 7, 2024, after theU.S.financial markets close.

Dynavaxwill host a conference call and live audio webcast onThursday, November 7, 2024, at4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website athttps://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using thecaller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

AboutDynavaxDynavaxis a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in theU.S., theEuropean UnionandGreat Britainfor the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines.Dynavaxis advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visitwww.dynavax.comand followDynavaxonLinkedInandTwitter.

For Investors/Media:Paul Coxpcox@dynavax.com510-665-0499

Nicole Arndtnarndt@dynavax.com510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-november-7-2024-302286555.html

SOURCEDynavax Technologies

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com